Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qiwei Tongbi
- Development stage
- Unknown
- Lead developer
- Jiangsu Kanion Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Qiwei Tongbi is a Traditional Chinese Medicine (TCM) oral liquid formulation developed by Jiangsu Kanion Pharmaceutical for the treatment of rheumatoid arthritis (RA). The formula is composed of seven active components, including ants (*Polyrhachis vicina*), *Sinomenium acutum*, *Millettia dielsiana*, and *Pyrola calliantha*. It functions as an anti-inflammatory and immunomodulatory agent by suppressing pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interleukin-17 (IL-17). Additionally, it modulates the NF-kappaB and RANK/RANKL signaling pathways, which are critical in the pathogenesis of joint destruction and synovial hyperplasia in RA. Clinical studies have demonstrated that Qiwei Tongbi effectively reduces C-reactive protein (CRP) levels and improves patient-reported outcomes, including pain (VAS) and physical function (HAQ), particularly in patients with stable, long-standing disease.
- Brand names
- Qiwei TongbiQiwei Tongbi Oral Liquid
- Other names
- Qiwei Tongbi Koufuye
02
Targets
IL-6 (Interleukin 6)NF-κBRANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Qiwei Tongbi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qiwei Tongbi.